| Pharmacologic inhibition of STAT5 in acute myeloid leukemia B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ... Leukemia 32 (5), 1135-1146, 2018 | 147 | 2018 |
| Direct targeting options for STAT3 and STAT5 in cancer A Orlova, C Wagner, ED de Araujo, D Bajusz, HA Neubauer, M Herling, ... Cancers 11 (12), 1930, 2019 | 79 | 2019 |
| Structural and functional consequences of the STAT5BN642H driver mutation ED de Araujo, F Erdogan, HA Neubauer, D Meneksedag-Erol, ... Nature communications 10 (1), 2517, 2019 | 78 | 2019 |
| CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence N Garg, D Bakhshinyan, C Venugopal, S Mahendram, DA Rosa, ... Oncogene 36 (5), 606-617, 2017 | 65 | 2017 |
| Structural implications of STAT3 and STAT5 SH2 domain mutations ED de Araujo, A Orlova, HA Neubauer, D Bajusz, HS Seo, ... Cancers 11 (11), 1757, 2019 | 58 | 2019 |
| JAK‐STAT core cancer pathway: an integrative cancer interactome analysis F Erdogan, TB Radu, A Orlova, AK Qadree, ED de Araujo, J Israelian, ... Journal of cellular and molecular medicine 26 (7), 2049-2062, 2022 | 49 | 2022 |
| The ERBB-STAT3 axis drives Tasmanian devil facial tumor disease L Kosack, B Wingelhofer, A Popa, A Orlova, B Agerer, B Vilagos, P Majek, ... Cancer Cell 35 (1), 125-139. e9, 2019 | 48 | 2019 |
| PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia JM Gawel, AE Shouksmith, YS Raouf, N Nawar, K Toutah, S Bukhari, ... European Journal of Medicinal Chemistry 201, 112411, 2020 | 39 | 2020 |
| Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities AM Ali, RF Gómez‐Biagi, DA Rosa, PS Lai, WL Heaton, JS Park, ... ChemMedChem 11 (8), 850-861, 2016 | 38 | 2016 |
| Characterization of conformationally constrained benzanilide scaffolds for potent and selective HDAC8 targeting MM Hassan, J Israelian, N Nawar, G Ganda, P Manaswiyoungkul, ... Journal of Medicinal Chemistry 63 (15), 8634-8648, 2020 | 35 | 2020 |
| Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer AE Shouksmith, F Shah, ML Grimard, JM Gawel, YS Raouf, M Geletu, ... Journal of medicinal chemistry 62 (5), 2651-2665, 2019 | 35 | 2019 |
| Development of HDAC inhibitors exhibiting therapeutic potential in T-cell prolymphocytic leukemia K Toutah, N Nawar, S Timonen, H Sorger, YS Raouf, S Bukhari, J von Jan, ... Journal of medicinal chemistry 64 (12), 8486-8509, 2021 | 29 | 2021 |
| Class I/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemia AE Shouksmith, JM Gawel, N Nawar, D Sina, YS Raouf, S Bukhari, L He, ... ACS Medicinal Chemistry Letters 11 (1), 56-64, 2019 | 26 | 2019 |
| High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains ED de Araujo, P Manaswiyoungkul, J Israelian, J Park, K Yuen, ... Journal of pharmaceutical and biomedical analysis 143, 159-167, 2017 | 21 | 2017 |
| Sensitive detection of broad-Spectrum bacteria with small-molecule fluorescent excimer chemosensors AD Cabral, N Rafiei, ED de Araujo, TB Radu, K Toutah, D Nino, ... ACS sensors 5 (9), 2753-2762, 2020 | 20 | 2020 |
| The first nucleotide binding domain of the sulfonylurea receptor 2A contains regulatory elements and is folded and functions as an independent module ED de Araujo, LK Ikeda, S Tzvetkova, V Kanelis Biochemistry 50 (31), 6655-6666, 2011 | 20 | 2011 |
| Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma N Nawar, S Bukhari, AA Adile, Y Suk, P Manaswiyoungkul, K Toutah, ... Journal of medicinal chemistry 65 (4), 3193-3217, 2022 | 19 | 2022 |
| Unique molecular interaction with the histone deacetylase 6 catalytic tunnel: crystallographic and biological characterization of a model chemotype OO Olaoye, PR Watson, N Nawar, M Geletu, A Sedighi, S Bukhari, ... Journal of medicinal chemistry 64 (5), 2691-2704, 2021 | 18 | 2021 |
| Physiological characterization and light response of the CO2-concentrating mechanism in the filamentous cyanobacterium Leptolyngbya sp. CPCC 696 ED de Araujo, J Patel, C de Araujo, SP Rogers, SM Short, DA Campbell, ... Photosynthesis research 109, 85-101, 2011 | 18 | 2011 |
| Targeting prenylation inhibition through the mevalonate pathway P Manaswiyoungkul, ED de Araujo, PT Gunning RSC Medicinal Chemistry 11 (1), 51-71, 2020 | 17 | 2020 |
